BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B

Levodopa

The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

297+ PubMed studies analyzed · 20 RCTs · Evidence Score: 46.8

Research Domains

Levodopa has been studied across 19 research domains including 🧠 Neuroprotection, 🧠 Focus & Attention, 🌤️ Mood & Depression, ✨ Skin & Hair, ❤️ Cardiovascular. The primary research focus is 🧠 Neuroprotection with 71% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Levodopa, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Methyldopa
15 shared targets
Ampicillin
7 shared targets
Diiodotyrosine
9 shared targets
Demeclocycline
10 shared targets
Cefixime
8 shared targets
Cisplatin
8 shared targets
Carmine
6 shared targets
Idarubicin
11 shared targets
Sulpiride
7 shared targets
benzolamide
6 shared targets
Loading evidence profile...

This evidence profile for Levodopa is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.